4//SEC Filing
Boudes Pol F 4
Accession 0000899243-21-013816
CIK 0001133416other
Filed
Mar 28, 8:00 PM ET
Accepted
Mar 29, 4:35 PM ET
Size
8.1 KB
Accession
0000899243-21-013816
Insider Transaction Report
Form 4
Boudes Pol F
Chief Medical Officer
Transactions
- Award
Stock option (right to buy)
2021-03-25+50,000→ 50,000 totalExercise: $2.11Exp: 2031-03-25→ Common Stock (50,000 underlying) - Award
Stock option (right to buy)
2021-03-25+100,000→ 100,000 totalExercise: $2.11Exp: 2031-03-25→ Common Stock (100,000 underlying)
Footnotes (3)
- [F1]The options were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan.
- [F2]Such options vest as follows: 25% on each on September 30, 2021, March 31, 2022, September 30, 2022 and March 31, 2023.
- [F3]Such options vest when (i) the Company has received the interim results of its NAVIGATE clinical trial and (ii) makes a public announcement that it has received the interim results.
Documents
Issuer
GALECTIN THERAPEUTICS INC
CIK 0001133416
Entity typeother
Related Parties
1- filerCIK 0001454771
Filing Metadata
- Form type
- 4
- Filed
- Mar 28, 8:00 PM ET
- Accepted
- Mar 29, 4:35 PM ET
- Size
- 8.1 KB